The End of Shots? 5 Biotech Stocks Rethinking Diabetes
PR Newswire —
Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, Dec. 31, 2025 /PRNewswire/ -- USA News Group News Commentary – Recent clinical trials achieving 83% insulin independence rates have ignited a dramatic shift in metabolic disease investment[1], with late-2025 M&A activity reaching...